Discontinuation rates of warfarin vs direct acting oral anticoagulants in US clinical practice: Results from ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
American Heart Journal May 06, 2020
Jackson LR, Kim S, Blanco R, et al. - Given that although oral anticoagulation represents a cornerstone of stroke prevention treatment in atrial fibrillation (AF), few investigations have assessed comparative discontinuation rates in clinical practice, so researchers determined discontinuation rates in patients receiving warfarin and direct oral anticoagulants (DOACs) in clinical practice. The ORBIT-AF II Registry was used, which incorporated 10,005 total AF patients with a CHA2DS2VASc score of ≥ 2 on warfarin or DOACs from 235 clinical practices across the US from February 13, 2013 and July 12, 2017. Findings revealed higher adjusted rates of discontinuation in DOAC-treated vs vitamin K anticoagulants-treated patients at 12-months in a community based AF cohort. Experts also noted increased absolute risk of all-cause mortality and cardiovascular death in relation to discontinuation of oral anticoagulation.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries